Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.
The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.
Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.
Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.
In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.
Daxor Corporation (NYSE: DXR) announced significant findings at the NeuroCritical Care Society's 19th Annual Meeting, showcasing the effectiveness of their BVA-100 blood test in managing non-traumatic subarachnoid hemorrhage (nSAH). The study revealed that 69% of physicians altered their treatment strategies based on BVA results, preferring it over invasive methods. Previous studies indicated a 54% change in management and a 66% reduction in ICU mortality linked to BVA tests. These results underscore Daxor's role in improving patient outcomes through enhanced blood volume management.
Daxor Corporation (NYSE: DXR) has been awarded a SBIR/STTR matching fund grant of $200K from Launch Tennessee, linked to a Phase II award from the Department of Defense. This funding will support the development of their next-generation point-of-care blood volume analyzer. The grant is part of a competitive selection aimed at encouraging innovation and job creation in Tennessee, where over 80 applications were received. Daxor's CEO highlighted the importance of this grant for advancing their technology and enhancing patient outcomes.
Daxor Corporation (NYSE: DXR) presented new findings at the Heart Failure Society of America Annual Scientific Meeting 2021, emphasizing the significance of the BVA-100 blood test in managing heart failure. The data illustrated the test's effectiveness in tailoring treatment for patients, especially those with left ventricular assist devices. Notably, studies highlighted improved outcomes for hospitalized patients through blood volume analysis and ultrafiltration techniques. Ongoing clinical trials aim to apply BVA-100 in various settings, enhancing care for over one million heart failure patients in the U.S.
Daxor (NYSE: DXR) will showcase its blood volume measurement technology at the Heart Failure Society of America Annual Scientific Meeting from September 10-13, 2021. The event will feature new clinical trials demonstrating the effectiveness of the BVA-100 test. Daxor's Chief Scientific Officer stated this year’s program is the most comprehensive in the company’s history, highlighting outcomes in patients with left ventricular assist devices and heart failure. The company aims to improve patient outcomes through important clinical studies funded by NIH and the Department of Defense, impacting over 7 million patients in the U.S.
Daxor, a leader in blood volume measurement technology, announced that CEO Michael Feldschuh will present at the 23rd Annual H.C. Wainwright Global Investment Conference held virtually from September 13-15, 2021. His presentation will cover the company's latest updates, business model, and growth strategy, available from September 13th at 7:00 AM ET. Investors can register for the conference and schedule one-on-one meetings with Feldschuh. Daxor is known for the BVA-100, the first FDA-cleared diagnostic blood test for precise blood volume quantification.
Daxor Corporation (NYSE: DXR) announced significant growth in its blood volume diagnostic division, reporting a 26.5% increase in revenue for H1 2021 versus the prior year. CEO Michael Feldschuh highlighted plans for a new point-of-care blood volume analyzer launching in 2022, developed alongside the US DOD. Daxor’s strategy includes strong commercialization, next-gen product development, and improved clinical outcomes, supported by NIH funding for heart failure research. The company aims to expand its market reach significantly, leveraging both internal and external sales forces to enhance performance.
Daxor Corporation (NYSE: DXR) reports a 26.5% revenue increase in its diagnostic division, driven by the commercialization of the BVA-100® Blood Volume Analyzer and new distributor agreements. The company anticipates further growth through a multi-channel distribution model and has opened eight new accounts in 2021. Daxor's next-gen analyzers are set for production in 2022, supported by funding from the U.S. Department of Defense. Despite a 7% decrease in net assets to $14.5 million, the company remains optimistic about its commercialization strategy amidst ongoing COVID-19 challenges.
Daxor Corporation (NYSE: DXR) recently announced the publication of new data in Critical Care, highlighting the effectiveness of its BVA-100 diagnostic blood test in assessing blood volume alterations in critically ill COVID-19 patients. The research reveals significant capillary damage and blood volume deficits in these patients, emphasizing the need for fluid management. Following this, a multi-center study is underway at prominent hospitals including Wake Forest and NYU Langone Health to further explore these findings, potentially enhancing clinical outcomes.
Daxor Corporation (NYSE: DXR) has announced a distribution agreement with Concordance Healthcare Solutions, enhancing the availability of its BVA-100® diagnostic blood test across U.S. healthcare facilities. This partnership aims to promote blood volume measurement for improved patient outcomes in conditions like heart failure. Daxor's CEO, Michael Feldschuh, emphasized that this collaboration will boost sales and awareness of their technology. Concordance's Senior Director highlighted that the BVA-100 will help reduce readmissions and healthcare costs, positively impacting patient care.
Daxor Corporation (NYSE: DXR) announced an expert analysis titled, "Anemia and Heart Failure: Guidance for Clinicians and Trialists," published in the American College of Cardiology. This analysis highlights the significance of measuring total blood volume in managing anemia among heart failure patients, a condition affecting over 6 million Americans. Daxor's BVA-100 Blood Volume Analyzer is emphasized as a critical tool for accurate blood volume assessment, informing treatment strategies. The company is also developing new testing platforms supported by the U.S. Department of Defense and NIH, expected in 2022.
FAQ
What is the current stock price of DAXOR (DXR)?
What is the market cap of DAXOR (DXR)?
What does Daxor Corporation specialize in?
What is the BVA-100?
How has the BVA-100 improved blood volume measurement?
What are some recent achievements of Daxor Corporation?
How has Daxor performed financially in early 2024?
Who is the Investor Relations Contact at Daxor Corporation?
What kind of medical events does Daxor participate in?
Where has Daxor Corporation published its research findings?
What is the significance of the BVA-100 in medical practice?
Where is Daxor Corporation headquartered?
